Tretinoin, the first successful differentiating agent, approed by FDA for use in acute promyelocytic leukemia.

FDA批准首个有效的促分化药物-维A酸治疗急性早幼粒细胞白血病.

互联网

Objective To observe the clinical effects of all - trans - retinoic acid ( ATRA ) in treating 11 patients with acute promyelocytic leukemia ( APL ).

目的观察11例急性早幼粒细胞性白血病患者经全反式 维 甲酸 治疗后的临床效果.

互联网

Tretinoin, the first successful differentiating agent , approved by FDA for use in acute promyelocytic leukemia.

fda批准首个有效的促分化药物-维A酸治疗急性早幼粒细胞白血病.

互联网

Fortunately, these conditions are uncommon in patients with hematologic malignancies, with the exception of promyelocytic leukemia.

所幸的是, 除了早幼粒细胞白血病, 这种情况在恶性血液疾病患者中并不常见.

互联网

IntroductionAll - trans retinoic acid ( ATRA ) is efficiently differentiation in - ducer for acute promyelocytic leukemia ( APL ).

全反式维甲酸 ( ATRA ) 用于急性早幼粒细胞白血病 ( APL) 的诱导分化治疗,有很高的完全缓解(CR ) 率,现已成为APL诱导缓解治疗的首选药物.

互联网